IL7R and acute lymphoblastic leukemia: Exploring the therapeutic potential of targeting JAK/STAT pathway (IL7/IL7R signaling) with small molecular inhibitors to sensitize Zeb2Tg ETP-ALL to LSD1i (GSK-LSD1)